Leqselvi FDA Approval History
Last updated by Judith Stewart, BPharm on July 26, 2024.
FDA Approved: Yes (First approved July 25, 2024)
Brand name: Leqselvi
Generic name: deuruxolitinib phosphate
Dosage form: Tablets
Company: Sun Pharmaceutical Industries Inc.
Treatment for: Alopecia Areata
Leqselvi (deuruxolitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata.
- Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body.
- Leqselvi contains deuruxolitinib, a JAK1/JAK2 inhibitor that works in the treatment of alopecia areata by targeting the γc cytokine and interferon-gamma (IFN-γ) signaling pathway to reverse hair loss.
Development timeline for Leqselvi
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
